Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUNX1 | Q01196 | 6/20 | 0.43 |
| ▸ | CBFB | Q13951 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9531062 | 0.88 | USP30 (0.36) | RUNX1CBFBTRPV1KIF11KDM4E | |
| SCHEMBL2108297 | 0.87 | RUNX1 (0.56) | RUNX1CBFBTRPV1KIF11GAA | |
| SCHEMBL9456203 | 0.86 | TRPV1 (0.45) | RUNX1CBFBTRPV1KIF11KDM4E | |
| SCHEMBL9687343 | 0.83 | TRPV1 (0.38) | RUNX1CBFBTRPV1SCN10ALMNA | |
| SCHEMBL11903454 | 0.81 | KDM4E (0.47) | RUNX1CBFBTRPV1KIF11KDM4E | |
| SCHEMBL18190876 | 0.81 | RUNX1 (0.43) | RUNX1CBFBTRPV1KIF11KDM4E | |
| SCHEMBL1193332 | 0.81 | RUNX1 (0.43) | RUNX1CBFBTRPV1KIF11KDM4E | |
| SCHEMBL482378 | 0.81 | NPC1 (0.41) | KDM4EGAAKMT2ANPC1RAB9A | |
| SCHEMBL9674984 | 0.81 | NPSR1 (0.53) | RUNX1CBFBTRPV1KIF11KDM4E | |
| SCHEMBL7066940 | 0.81 | RUNX1 (0.43) | RUNX1CBFBTRPV1KIF11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104836-A1 | TRANSFER FILM AND METHOD FOR PRODUCING LAMINATE | FUJIFILM CORPORATION (JP) | 2023-04-06 | — | — | US | disclosed |
| US-20230025871-A1 | TRANSFER FILM, LAMINATE, ACOUSTIC SPEAKER, AND METHOD FOR PRODUCING LAMINATE | FUJIFILM CORPORATION (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220004102-A1 | TRANSFER FILM FOR SILVER CONDUCTIVE MATERIAL PROTECTIVE FILM, MANUFACTURING METHOD OF PATTERNED SILVER CONDUCTIVE MATERIAL, LAMINATE, AND TOUCH PANEL | FUJIFILM CORPORATION (JP) | 2022-01-06 | — | — | US | disclosed |
| US-20210198406-A1 | TRANSFER FILM, MANUFACTURING METHOD OF CURED FILM, MANUFACTURING METHOD OF LAMINATE, AND MANUFACTURING METHOD OF TOUCH PANEL | FUJIFILM CORPORATION (JP) | 2021-07-01 | — | — | US | disclosed |
| US-8163768-B2 | 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus | AVENTIS PHARMA S.A.. (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-1910366-B1 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1910366-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| EP-0134400-B1 | FLUOROALKOXYSUBSTITUTED PYRIDYLMETHYLTHIO-(OR SULFINYL-)BENZIMIDAZOLES HAVING A SECRETOLYTIC ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1993-03-24 | — | — | EP | disclosed |
| WO-1989005299-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1989-06-15 | — | — | WO | disclosed |
| US-4758579-A | e.g. pantoprazole or pantoprazole sodium | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-07-19 | — | — | US | disclosed |
| US-4686230-A | Picoline derivative useful as gastric acid secretion inhibitors | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1987-08-11 | — | — | US | disclosed |
| EP-0201575-A1 | NEW PICOLINE DERIVATIVES, PREPARATION PROCESS THEREOF, UTILIZATION THEREOF AND DRUGS CONTAINING THEM. | BYK GULDEN LOMBERG CHEM FAB (DE) | 1986-11-20 | — | — | EP | disclosed |
| EP-0200777-A1 | NEW AMINO COMPOUNDS, PREPARATION PROCESS THEREOF, UTILIZATION THEREOF AND DRUGS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
| WO-1986002645-A1 | NEW AMINO COMPOUNDS, PREPARATION PROCESS THEREOF, UTILIZATION THEREOF AND DRUGS CONTAINING THEM | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT M (DE) | 1986-05-09 | — | — | WO | disclosed |
| WO-1986002646-A1 | NEW PICOLINE DERIVATIVES, PREPARATION PROCESS THEREOF, UTILIZATION THEREOF AND DRUGS CONTAINING THEM | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT M (DE) | 1986-05-09 | — | — | WO | disclosed |
| EP-0166287-A1 | Dialkoxyridines, process for their preparation, their application and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
| US-4555518-A | ANTIULCER AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1985-11-26 | — | — | US | disclosed |
| EP-0134400-A2 | Fluoroalkoxysubstituted pyridylmethylthio-(or sulfinyl-)benzimidazoles having a secretolytic activity | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | DPYD, DHPS, QDPR | RUNX1 907/4885CBFB 3043/4885TRPV1 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.